Cambridge, Mass., (August 30, 2005) -- Ensemble Discovery Corporation today announced the appointment of Jean-Jacques Bienaime to its Board of Directors. Mr. Bienaime is currently the Chief Executive Officer of BioMarin Pharmaceuticals Inc.
"I am excited to join Ensemble Discovery’s Board of Directors," said Mr. Bienaime, "Ensemble Discovery is an innovative company developing the commercial potential of DNA Programmed Chemistry TM . I look forward to working with the Company’s Board and talented team as it develops programs to address unmet needs in multiple markets, including Life Sciences, materials and chemicals."
Noubar B. Afeyan, Ph.D., Chairman of Ensemble Discovery’s Board of Directors and Managing Partner of Flagship Ventures, said "We are fortunate to have someone with JJ’s experience and skill on our Board. With more than 25 years of experience in the biotechnology and pharmaceutical industries, JJ brings an invaluable perspective to the Board of Ensemble Discovery."
About Mr. Bienaime
Mr. Bienaime joined BioMarin Pharmaceuticals Inc. in May 2005 as chief executive officer and member of the board of directors. From November 2002 to until its sale to Danisco in the spring of 2005, Mr. Bienaime served as chairman, chief executive officer, and president of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. From 1998 to late 2002, Mr. Bienaime served as chairman, chief executive officer and president of Sangstat Medical Corporation, an immunology-focused biotechnology company. From 1992 to 1998, Mr. Bienaime held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis). Earlier in his career, he worked at Genentech, Inc.
Mr. Bienaime received an M.B.A from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the Ecole Superieure de Commerce de Paris.
About Ensemble Discovery Corporation
Ensemble Discovery Corporation, located in Cambridge, MA, is an early stage company that is transforming the way scientists discover new chemical reactions. Based on the groundbreaking work of Professor David Liu of Harvard University, DNA Programmed Chemistry (DPC)(TM) utilizes nature’s approach to controlling chemical reactivity. Ensemble has integrated DPC(TM) into a unique selection system that combines biology, chemistry and nanotechnology to discover novel compounds and address significant unmet needs in therapeutics, biodetection and other specialty chemical markets.
Richard F. Begley, Ph.D.
Ensemble Discovery Corporation